SCHEMBL2743262

SCHEMBL2743262

CN1CCC(C(N)=O)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12457873 1.00
SCHEMBL13748108 1.00
SCHEMBL12310449 0.87 BCHE (0.54)
SCHEMBL4498148 0.87 BCHE (0.54)
SCHEMBL735137 0.87 BCHE (0.54)
SCHEMBL11039671 0.86 SMN1; SMN2 (0.59)
SCHEMBL274448 0.86 SMN1; SMN2 (0.59)
Hydrochloric Acid SCHEMBL6500960 0.85 BCHE (0.53)
Hydrochloric Acid SCHEMBL4788803 0.84 SMN1; SMN2 (0.57)
Hydrochloric Acid SCHEMBL14311961 0.84 SMN1; SMN2 (0.57)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4532503-A1 HALOINDOLE MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER F. Hoffmann-La Roche AG (CH) 2025-04-09 EP claimed
CN-115335369-B GEM-disubstituted piperidine melanocortin subtype-2 receptor (MC 2R) antagonists and uses thereof 克林提克斯医药股份有限公司 2024-07-02 CN claimed
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US claimed
WO-2023232776-A1 HALOINDOLE MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2023-12-07 WO claimed
CN-115335369-A GEM-disubstituted piperidine melanocortin subtype-2 receptor (MC 2R) antagonists and uses thereof 克林提克斯医药股份有限公司 2022-11-11 CN claimed
CN-108699035-A Noval chemical compound 特殊治疗有限公司 2018-10-23 CN claimed
CN-108699106-A Novel trifluoromethyl propanamide derivative as HTRA1 inhibitor 豪夫迈·罗氏有限公司 2018-10-23 CN claimed
EP-2729459-B1 SUBSTITUTED AZAHETEROCYCLES FOR THE TREATMENT OF CANCER MERCK PATENT GMBH (DE) 2018-08-22 EP claimed
US-9199962-B2 Substituted azaheterocycles for the treatment of cancer MERCK PATENT GMBH (DE) 2015-12-01 US claimed
US-20140221366-A1 Substituted Azaheterocycles for the Treatment of Cancer MERCK PATENT GMBH (DE) 2014-08-07 US claimed
EP-2729459-A1 SUBSTITUTED AZAHETEROCYCLES FOR THE TREATMENT OF CANCER Merck Patent GmbH (DE) 2014-05-14 EP claimed
US-8431565-B2 Substituted imidazoheterocycles CARA THERAPEUTICS, INC. (US) 2013-04-30 US claimed
WO-2013004332-A1 SUBSTITUTED AZAHETEROCYCLES FOR THE TREATMENT OF CANCER MERCK PATENT GMBH (DE) 2013-01-10 WO claimed
US-20090149450-A1 SUBSTITUTED IMIDAZOHETEROCYCLES CARA THERAPEUTICS, INC. (US) 2009-06-11 US claimed
US-20260069605-A1 KRAS INHIBITORS INCYTE CORP (US) 2026-03-12 US disclosed
US-20250236608-A1 EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION 2025-07-24 US disclosed
EP-4532503-A1 HALOINDOLE MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER F. Hoffmann-La Roche AG (CH) 2025-04-09 EP disclosed
US-5969131-A OR PRECURSORS; CHEMICAL INTERMEDIATES SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1999-10-19 US disclosed
US-5708165-A ISOMERIZATION IN SOLVENT OF CEPHALOSPORINS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1998-01-13 US disclosed
EP-0634415-A2 Cephem compound, its production and its use for producing cephem antibiotics SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1995-01-18 EP disclosed